Pure Global
NCT06380699

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single and Multiple Doses
Changzhou Qianhong Bio-pharma Co., Ltd.·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
QHRD106 Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Changzhou Qianhong Bio-pharma Co., Ltd.
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 16, 2023
End date
Dec 25, 2023
Enrollment
56 participants
Primary outcome

Safety as assessed by incidence, severity, and causality of adverse events,Plasma measurements of QHRD106,Concentration of bradykinin in plasma

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and
 pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06380699
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06380699 through Pure Global AI's free database. This Phase 1 trial is sponsored by Changzhou Qianhong Bio-pharma Co., Ltd. and is currently Completed. The study focuses on Acute Ischemic Stroke. Target enrollment is 56 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.